TY - JOUR
T1 - Data generated by quantitative LC-MS proteomics are only the start and not the endpoint: Optimization of QconCAT-based measurement of hepatic UDP-glucuronosyltransferase enzymes with reference to catalytic activity
AU - Achour, Brahim
AU - Dantonio , Alyssa L
AU - Niosi, Mark
AU - Novak, Jonathan J
AU - Al-Majdoub, Zubida
AU - Goosen, Theunis C
AU - Rostami-Hodjegan, Amin
AU - Barber, Jill
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Quantitative proteomic methods require optimization at several stages, including sample preparation, LC-MS/MS and data analysis, with the final analysis stage being less widely appreciated by end-users. Achour et al. (2017; Drug Metabolism and Disposition, 45: 1102-1112) previously reported measurement of eight uridine-5'-diphospho-glucuronosyltransferases (UGT) generated by two laboratories [using stable isotope-labeled (SIL) peptides or quantitative concatemer (QconCAT)], which reflected significant disparity between proteomic methods. Initial analysis of QconCAT data showed lack of correlation with catalytic activity for several UGTs (1A4, 1A6, 1A9, 2B15) and moderate correlations for UGTs 1A1, 1A3 and 2B7 (Rs=0.40-0.79, p<0.05; R2=0.30); good correlations were demonstrated between cytochrome P450 activities and abundances measured in the same experiments. Consequently, a systematic review of data analysis, starting from unprocessed LC-MS/MS data, was undertaken, with the aim of improving accuracy, defined by correlation against activity. Three main criteria were found to be important: choice of monitored peptides and fragments, correction for isotope-label incorporation, and abundance normalization using fractional protein mass. Upon optimization, abundance-activity correlations improved significantly for six UGTs (Rs=0.53-0.87, p<0.01; R2=0.48-0.73); UGT1A9 showed moderate correlation (Rs=0.47, p=0.02; R2=0.34). No spurious abundance-activity relationships were identified. However, methods remained sub-optimal for UGT1A3 and UGT1A9; here hydrophobicity of standard peptides is believed to be limiting. This commentary provides a detailed data analysis strategy and indicates, using examples, the significance of systematic data processing following acquisition. The proposed strategy offers significant improvement on existing guidelines applicable to clinically-relevant proteins quantified using QconCAT.
AB - Quantitative proteomic methods require optimization at several stages, including sample preparation, LC-MS/MS and data analysis, with the final analysis stage being less widely appreciated by end-users. Achour et al. (2017; Drug Metabolism and Disposition, 45: 1102-1112) previously reported measurement of eight uridine-5'-diphospho-glucuronosyltransferases (UGT) generated by two laboratories [using stable isotope-labeled (SIL) peptides or quantitative concatemer (QconCAT)], which reflected significant disparity between proteomic methods. Initial analysis of QconCAT data showed lack of correlation with catalytic activity for several UGTs (1A4, 1A6, 1A9, 2B15) and moderate correlations for UGTs 1A1, 1A3 and 2B7 (Rs=0.40-0.79, p<0.05; R2=0.30); good correlations were demonstrated between cytochrome P450 activities and abundances measured in the same experiments. Consequently, a systematic review of data analysis, starting from unprocessed LC-MS/MS data, was undertaken, with the aim of improving accuracy, defined by correlation against activity. Three main criteria were found to be important: choice of monitored peptides and fragments, correction for isotope-label incorporation, and abundance normalization using fractional protein mass. Upon optimization, abundance-activity correlations improved significantly for six UGTs (Rs=0.53-0.87, p<0.01; R2=0.48-0.73); UGT1A9 showed moderate correlation (Rs=0.47, p=0.02; R2=0.34). No spurious abundance-activity relationships were identified. However, methods remained sub-optimal for UGT1A3 and UGT1A9; here hydrophobicity of standard peptides is believed to be limiting. This commentary provides a detailed data analysis strategy and indicates, using examples, the significance of systematic data processing following acquisition. The proposed strategy offers significant improvement on existing guidelines applicable to clinically-relevant proteins quantified using QconCAT.
KW - Drug development/discovery
KW - Enzyme kinetics
KW - Glucuronidation/UDP-glucuronyltransferases/UGT
KW - In vitro-in vivo prediction (IVIVE)
KW - Proteomics
U2 - 10.1124/dmd.117.079475
DO - 10.1124/dmd.117.079475
M3 - Article
SN - 0090-9556
VL - 46
SP - 805
EP - 812
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 6
ER -